Staging versus Biology in Breast Cancer
Kathy S. Albain, MD, discusses staging versus biology in breast cancer.
Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses staging versus biology in breast cancer.
Clinical Pearls
- When patients have high-stage disease signified by many positive nodes, larger tumor, or aggressive biologic features, a physician’s decision is more straightforward
- When a patient’s stage of disease, tumor volume or disease burden is high but the biology of the cancer appears to be favorable or when a patient with small tumors has an aggressive or unfavorable biology, it is more challenging for a physician to decide on treatment
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
